These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 14965150)

  • 41. Proposed NSAID package insert labeling.
    Food and Drug Administration U.S. Public Health Service
    J Pain Palliat Care Pharmacother; 2006; 20(1):49-55. PubMed ID: 16687359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Compounding pharmacy conundrum: "we cannot live without them but we cannot live with them" according to the present paradigm.
    Guharoy R; Noviasky J; Haydar Z; Fakih MG; Hartman C
    Chest; 2013 Apr; 143(4):896-900. PubMed ID: 23412546
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Descriptive analysis of primary package labels from commercially available prescription solid oral dosage form drugs.
    Chermak TE; Lambert BL
    J Am Pharm Assoc (2003); 2009; 49(3):399-406. PubMed ID: 19443320
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inappropriate dosage instructions in package inserts.
    Fuchs J; Hippius M
    Patient Educ Couns; 2007 Jul; 67(1-2):157-68. PubMed ID: 17451909
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Uses of drugs not described in the package insert (off-label uses).
    Committee on Drugs. American Academy of Pediatrics
    Pediatrics; 2002 Jul; 110(1 Pt 1):181-3. PubMed ID: 12093968
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A study of the nonprescription drug consumer's understanding of the ranitidine product label and actual product usage patterns in the treatment of episodic heartburn.
    Ciociola AA; Sirgo MA; Pappa KA; McGuire JA; Fung K
    Am J Ther; 2001; 8(6):387-98. PubMed ID: 11704777
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of German package inserts.
    Fuchs J; Hippius M; Schaefer M
    Int J Clin Pharmacol Ther; 2006 Jan; 44(1):8-13. PubMed ID: 16425965
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Critical Evaluation of Pharmacogenetic Information in Package Inserts for Selected Drugs Marketed in India and Its Comparison With US FDA-Approved Package Inserts.
    Pai SA; Kshirsagar N
    J Clin Pharmacol; 2016 Oct; 56(10):1232-42. PubMed ID: 26873003
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
    Kweder SL
    Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
    [No Abstract]   [Full Text] [Related]  

  • 51. Law-medicine notes. Package inserts for patients: informed consent in the 1980s.
    Curran WJ
    N Engl J Med; 1981 Dec; 305(26):1564-6. PubMed ID: 7311994
    [No Abstract]   [Full Text] [Related]  

  • 52. The patient's understanding of the oral contraceptive patient package insert.
    Casey FG; Fluitt DM; Wiatt AL
    Mil Med; 1983 Mar; 148(3):276-8. PubMed ID: 6408516
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety.
    Kesselheim AS
    Clin Pharmacol Ther; 2010 Jun; 87(6):645-7. PubMed ID: 20485322
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Compounding pharmacy industry has outgrown its regulatory system, ASHP and FDA say.
    Thompson CA
    Am J Health Syst Pharm; 2013 May; 70(9):747-8. PubMed ID: 23592352
    [No Abstract]   [Full Text] [Related]  

  • 55. Pharmaceutical inserts: legal consequences.
    Hirsh HL
    Hosp Med Staff; 1979 Jul; 8(7):2-6. PubMed ID: 10242674
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patient package inserts and the pharmacist's responsibility.
    Fink JL
    Am J Hosp Pharm; 1979 Feb; 36(2):226-9. PubMed ID: 420215
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Physicians, pharmacists, pharmaceutical manufacturers: partners in patient care, partners in litigation?
    Willig SH
    Spec Law Dig Health Care (Mon); 1987 Feb; 8(12):7-40. PubMed ID: 10280590
    [No Abstract]   [Full Text] [Related]  

  • 58. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability.
    Green W
    Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019
    [No Abstract]   [Full Text] [Related]  

  • 59. Differences in product information of biopharmaceuticals in the EU and the USA: implications for product development.
    Nieminen O; Kurki P; Nordström K
    Eur J Pharm Biopharm; 2005 Aug; 60(3):319-26. PubMed ID: 15996576
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Radiopharmaceutical regulation and Food and Drug Administration policy.
    Rotman M; Laven D; Levine G
    Semin Nucl Med; 1996 Apr; 26(2):96-106. PubMed ID: 8723504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.